Microvascular Therapeutics

MVT Pharma is a late-clinical stage biotech with near-term value inflection points. Its pipeline features a best-in-class microbubble contrast agent for echocardiography that has completed phase II and a Department of Defense-funded nanobubble therapeutic, which offers a faster, less expensive FDA device pathway to the multi-billion-dollar myocardial infarction market.